secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-12-30T23:59:59+00:00
Accession:  0000950170-24-140949
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome AXS-05 succeeds in ACCORD-2 Phase 3 for Alzheimer's agitation; ADVANCE-2 misses primary endpoint
--------------------------------------------------------------------------------

- ACCORD-2 met primary endpoint: time to relapse delayed (HR=0.276, p=0.001); 3.6-fold lower relapse risk vs placebo.
- ADVANCE-2 did not reach statistical significance on primary endpoint (CMAI change: -13.8 vs -12.6, p=NS); results numerically favored AXS-05.
- No deaths, no increased falls, sedation, or cognitive decline in any trial; long-term safety in >300 patients for 6 months.
- Three of four pivotal Phase 3 trials now positive; company plans NDA submission to FDA in second half 2025.
- AXS-05 holds Breakthrough Therapy designation for Alzheimer's disease agitation since June 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/0000950170-24-140949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024140949/axsm-20241230.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-140949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer